Something to think about on thanksgiving.
Why insurance companies are excited about Afrezza
by pfg_01
.
Quote: "...a man diagnosed with type 2 diabetes between the ages of 25 and 44 can be expected to incur related costs of $124,700 over his lifetime. A woman diagnosed at the same age may incur related costs of $130,800 over her lifetime."
Quote: "Treating complications due to diabetes account for 53 percent of lifetime costs"
Source, article dated 08/08/13 titled "High Lifetime Costs for Type 2 Diabetes"
Afrezza is much safer then existing insulins that are currently approved and on the market (e.g. Afrezza significantly reduces risk of hypoglycemia and in addition is associated with less weight gain), plus in addition Afrezza increases compliance of usage by diabetics because it is inhaled and not administered via shots. Insurance companies are keenly aware that these benefits provided by Afrezza will significantly help them drive down the overall costs associated with diabetic complications. This in turn will benefit society as a whole, which supports much of their costs of health care via their taxes.
Diabetics will use Afrezza because it improves their quality of life. Doctors will prescribe Afrezza because of increased usage compliance. Insurers will strongly support and encourage usage of Afrezza because it saves them money. MNKD's big pharm partner will strongly market Afrezza because it will increase their own shareholder wealth.
Afrezza is a win-win-win-win for everyone except for MNKD "shorts", and existing insulins on the market, the big pharms associated with those existing insulins, and of course the shareholders of those big pharms.
